We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Rani Therapeutics Holdings Inc (RANI) USD0.0001 A

Sell:$3.10 Buy:$3.71 Change: $0.01 (0.31%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
Sell:$3.10
Buy:$3.71
Change: $0.01 (0.31%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
Sell:$3.10
Buy:$3.71
Change: $0.01 (0.31%)
Market closed |  Prices as at close on 22 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. The RaniPill capsule, the RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-101, RT-102, RT-105, RT-110 and RT-111. Its RT-101 is an Octreotide for the treatment of NETs and acromegaly. It manufactures and assembles RaniPill capsules at its facility in San Jose, California.

Contact details

Address:
2051 Ringwood Avenue
SAN JOSE
95131
United States
Telephone:
+1 (408) 4573700
Website:
https://www.ranitherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RANI
ISIN:
US7530181004
Market cap:
$163.99 million
Shares in issue:
50.00 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Mir Imran
    Executive Chairman of the Board
  • Talat Imran
    Chief Executive Officer, Director
  • Svai Sanford
    Chief Financial Officer
  • Mir Hashim
    Chief Scientific Officer
  • Eric Groen
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.